A New Nanoparticle (SpFN) Vaccine Candidate

Researchers have developed a promising new SARS-CoV-2 vaccine candidate that utilizes nanotechnology and shows robust, long-lived immunity in mouse models. According to this new study, the vaccine enhanced the recruitment of APCs (antigen-presenting cells), increased polyfunctional spike-specific T cells, with a bias towards TH1 responses, IFN-γ and TNFα as the dominant cytokines, and more robust SARS-CoV-2 spike-specific recall response and presented broad protection against other coronavirus strains.

The researchers have performed a thorough study of the vaccine-evoked innate and adaptive immune responses in mice against SARS-CoV-2. The study results have been published on a pre-print server. The researchers genetically linked the modified and stabilized prefusion-spike protein of the Wuhan-Hu-1 strain of SARS-CoV-2, to form a ferritin-fusion recombinant protein, which naturally forms a Spike-Ferritin nanoparticle (SpFN). hey then formulated it with either of the two distinct adjuvants used in this study: 1) Army Liposome Formulation containing the saponin, QS-21(ALFQ), and 2) Aluminum Hydroxide gel (Alhydrogel®) (AH).

Notably, the vaccine SpFN+ALFQ is currently in phase 1 clinical trial in the United States, sponsored by the U.S. Army (ClinicalTrials.gov Identifier: NCT04784767).  These findings have demonstrated a novel vaccine platform for SAR-CoV-2 that leverages the innate immune response to induce potent memory-specific antiviral T cells.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.biorxiv.org/content/10.1101/2021.04.28.441763v1

#Featured